SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

1 marketing jobs

Shionogi Inc. logo
2 days ago

Director, Channel & HCP Marketing

Shionogi Inc.

Florham Park, NJ (Hybrid)Full time$210K/yr – $250K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
Shionogi Inc. logo

Director, Channel & HCP Marketing

Shionogi Inc.

Florham Park, NJ (Hybrid)

$210K/yr - $250K/yrIn-houseFull-timeDirector/executive10+ years exp.
2 days ago
Shionogi Inc. logo
Shionogi Inc.

Director, Channel & HCP Marketing

Florham Park, NJ (Hybrid)

$210K/yr – $250K/yrDirector/Executive10+ years expFull time

Posted 2 days ago

  • Job
  • Company
  • Salaries
  • People
  • Funding
  • Audience
  • News
  • Links

Job Summary

Own the development and execution of channel and HCP marketing strategies across emerging care settings, omnichannel engagement, and non-personal promotion, aligning cross-functional teams to build differentiated commercial capabilities and optimize patient and HCP journeys.

  • Lead channel strategy across urgent care, telemedicine, retail, and other evolving sites of care.
  • Drive data-driven optimization and cross-functional collaboration to deliver differentiated commercial strategies.

Job Description

Responsibilities

  • Channel Strategy & Innovation
  • Develop and lead the company's channel marketing strategy across emerging and non-traditional healthcare settings, including urgent care, long-term care, telemedicine/virtual care, concierge medicine, retail and other evolving sites of care .
  • Identify opportunities to engage HCPs and healthcare decision-makers outside the traditional physician-office environment.
  • Develop channel-specific customer strategies based on HCP needs, behaviors, patient journeys, channel dynamics, and business priorities.
  • Assess emerging healthcare delivery models and identify opportunities to establish differentiated and scalable commercial capabilities.
  • Translate market and customer insights into actionable channel strategies, engagement models, and integrated marketing plans.
  • Establish frameworks to prioritize channels based on audience reach, customer value, engagement potential, and business impact.
  • HCP Marketing & Customer Engagement
  • Lead development of HCP marketing strategies that address the needs and behaviors of priority healthcare professionals across traditional and non-traditional care settings.
  • Develop differentiated HCP value propositions, messaging, content, and engagement strategies by audience and channel.

Requirements

  • Bachelor's degree required; advanced degree in business, marketing, healthcare, life sciences, or related field preferred.
  • 10+ years of progressive experience in pharmaceutical, biotechnology, healthcare, or related industries , with significant experience in commercial marketing.
  • Demonstrated experience developing and executing HCP marketing strategies within the pharmaceutical or biotechnology industry.
  • Significant experience in omnichannel marketing and non-personal promotion (NPP) , including development of integrated HCP engagement strategies.
  • Demonstrated experience developing strategies for non-traditional healthcare channels , such as urgent care, long-term care, telemedicine/virtual care, concierge medicine, retail healthcare, or other emerging sites of care.
  • Strong understanding of the U.S. healthcare ecosystem and evolving models of care.
  • Demonstrated ability to translate customer insights, data, and market dynamics into differentiated commercial strategies.
  • Experience working across Marketing, Sales, Medical Affairs, Market Access, Commercial Operations, Digital, Analytics, and other cross-functional teams.
  • Strong understanding of pharmaceutical promotional regulations and experience partnering with Legal/Regulatory/Medical functions.
  • Proven ability to influence senior leaders and operate effectively in a matrixed organization.

Preferred

  • Experience launching or supporting a pharmaceutical product in the U.S.
  • Experience building or transforming NPP and omnichannel capabilities .
  • Experience developing HCP strategies across multiple sites of care.
  • Experience with healthcare data, segmentation, targeting, customer analytics, and performance measurement.
  • Experience with digital health, virtual care, telemedicine, or other emerging healthcare models.
  • Experience integrating field force and non-personal promotion into a coordinated customer engagement strategy.
  • Experience working with media, digital, technology, and/or healthcare service partners.
  • Demonstrated ability to operate successfully in a fast-paced, entrepreneurial pharmaceutical environment.
Shionogi Inc. logo

Shionogi Inc.

Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19.Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for COVID-19 and advancing clinical programs in Fragile X syndrome, acute ischemic stroke as well metabolic disorders and oncology.Our team is driven to impact patient lives. Our partnerships with industry, government agencies, biotech companies and academia help to advance science with the urgency that today's health challenges demand. Through a combination of in-house discovery and strategic partnerships, we continue to deliver firsts for patients in the U.S. and worldwide. See our community guidelines: https://bit.ly/4n3Jhe4

Founded in 2001
Florham Park, New Jersey, USA
525 employees (23 in marketing)
www.shionogi.com

Salaries

Posted range

$210K/yr – $250K/yr

Taken straight from the job posting.

See all Shionogi Inc. salaries

Marketing Team

Marketing Team Size
23 (4% of company)
Median Tenure
1.2 years
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$382.6M
Last Raise
$375M
Grant, 1 years ago

Funding History

  • Jan 2025
    Grant • $375M
  • Mar 2018
    Grant • $7.6M

Traffic Signals

Monthly Visitors
75.5K
Traffic Source Mix
Search
63.5%
Direct
23.9%
Referral
10%
Social
1.1%
Paid
1.3%

Headcount Trend

Current headcount: ~527

Recent News

Shionogi & Co., Ltd. (OTCMKTS:SGIOF) Stock Price Down 3.4% – Here’s What Happened
Nov 12, 2025 • Defense World
Shionogi & Co. Announces Merger with Shionogi Pharma to Strengthen Supply Chain
Oct 26, 2025 • TipRanks
Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal
Sep 26, 2025 • IndiaTimes
Shares of Asian drugmakers drop after Trump imposes tariffs
Sep 26, 2025 • Straits Times
Shares of Asian drugmakers drop after Trump threatens tariffs
Sep 26, 2025 • MarketScreener
European drugmakers' shares hold firm, despite Trump tariffs
Sep 26, 2025 • MarketScreener
Shares of Asian drugmakers drop after Trump threatens tariffs
Sep 25, 2025 • Investing.com
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Sep 22, 2025 • BioSpace
Verrica Pharmaceuticals stock soars after Japan approves YCANTH
Sep 19, 2025 • Investing.com
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Sep 19, 2025 • Verrica Pharmaceuticals
Torii Pharma gains Japanese approval for Ycanth
Sep 19, 2025 • Pharma Letter
Shionogi strengthens position by acquiring Torii
Sep 17, 2025 • MarketScreener
Apnimed to Participate in Upcoming September Investor Conferences
Sep 15, 2025 • PR Newswire
Bioversys reports corporate highlights and key financials for the first half 2025
Sep 10, 2025 • PharmiWeb
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
Sep 10, 2025 • BioSpace
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
Sep 10, 2025 • BioVersys
Bioversys Reports Corporate Highlights and Key Financials For the First Half 2025
Sep 9, 2025 • Morningstar.com
FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP
Sep 5, 2025 • Infectious Disease Special Edition
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Sep 3, 2025 • Yahoo Finance
Fda accepts Shionogi's ensitrelvir nda for review as first oral therapy for prevention of Covid-19 following exposure
Sep 3, 2025 • MarketScreener
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
Sep 3, 2025 • PharmiWeb
Apnimed to Highlight AD109 and the Burden of Obstructive Sleep Apnea (OSA) at World Sleep Congress 2025
Sep 3, 2025 • PR Newswire
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
Sep 2, 2025 • Business Wire
FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention
Sep 2, 2025 • Contagion Live
Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs
Aug 18, 2025 • Bloomberg.com
U.S. Antiviral Drugs Market Size to Surpass USD 21.94 Billion By 2034
Aug 12, 2025 • BioSpace
Viral Vector Vaccines Strategic Business Research Report 2025 | Market to Reach $893.2 Million by 2030 - Pandemic-Era Acceleration of Vaccine Technologies Continues to Drive Viral Vector Advancements
Aug 12, 2025 • Research and Markets
Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge
Aug 11, 2025 • JAPAN Forward
Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs
Aug 8, 2025 • Nikkei Net
Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms
Aug 6, 2025 • EURACTIV
Biotech stars of 2024, did they shine or fade in 2025?
Jul 23, 2025 • Labiotech.eu
Japan In Vitro Diagnostics Market Report and Forecast 2025-2034
Jul 22, 2025 • Research and Markets
Antiviral Drugs Market Set to Reach USD 86.59 Billion by 2032, Driven by Rising Chronic Infections and Demand for Targeted Therapies - SNS Insider
Jul 17, 2025 • SNS Insider pvt ltd
ViiV Healthcare data show 89% of treatment-naïve people with HIV choose to switch to long-acting injectable Vocabria + Rekambys from daily pills after achieving rapid viral suppression
Jul 14, 2025 • Business Wire
Shionogi Implements Stibo Systems MDM Solution
Jul 10, 2025 • PR Newswire
Shionogi & Co., Ltd. Implements Stibo Systems MDM Solution
Jul 10, 2025 • MarketScreener
From Lab Bench to Bell Ring – Marc Gitzinger on BioVersys' road to IPO
Jul 8, 2025 • venturelab.swiss
Ceolia takes over from Shionogi in marketing of Actair in Japan
Jul 4, 2025 • Pharma Letter
Bioversys, Shionogi in CHF529M lung infection collaboration
Jul 3, 2025 • BioWorld MedTech
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
Jul 3, 2025 • Business Wire
Preparing Europe for the next cross-border health threats, COVID lessons unpacked
Jul 3, 2025 • EURACTIV
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
Jul 3, 2025 • BioSpace
Chronic Sialorrhea Market Size, Drug Pipeline Developments and Investment Trends 2024–2034
Jun 20, 2025 • PRLog
F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim
Jun 19, 2025 • BioSpace
F2G Announces Publication in The Lancet Infectious Diseases of Phase 2b Data Demonstrating Positive Therapeutic Responses in Patients with Serious Invasive Fungal Diseases Treated with Oral Olorofim
Jun 18, 2025 • F2G, Ltd.
Shionogi Completes Tender Offer for Torii Pharmaceutical, Acquiring 39% Stake
Jun 18, 2025 • MarketScreener
Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry
Jun 9, 2025 • Research and Markets
Peripheral Neuropathy Treatment Market Landscape 2025-2029: Robust Drug Pipeline to Expand the Market by $481 Million
Jun 6, 2025 • Research and Markets
The Pharma Letter M&A roundup - May 2025
Jun 4, 2025 • Pharma Letter
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants
Jun 3, 2025 • BioWorld MedTech
Raya Therapeutic Announces Two Posters at the ENCALS Meeting in Turin, Italy June 3-6
Jun 3, 2025 • EIN Presswire
BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants
Jun 2, 2025 • BioWorld MedTech
SHIONOGI & CO., LTD.
May 30, 2025 • MarketScreener
Shionogi & Co Ltd - Acceptance Of A New Drug Application For Naldemedine, A Treatment For Opioid-Induced Constipation, In China
May 30, 2025 • Reuters
Shionogi & Co Ltd - Acceptance Of A New Drug Application For Naldemedine, A Treatment For Opioid-Induced Constipation, In China
May 29, 2025 • MarketScreener
ViiV Healthcare Positive Perspectives 3 study finds widespread communication barriers: Half of people living with HIV feel unheard by healthcare providers despite high trust
May 28, 2025 • PharmiWeb
Global Liver Cirrhosis Market Insights 2025: Key Trends, Market Size, and Growth Forecast
May 13, 2025 • EIN Presswire
Epidermolysis Bullosa Market 2025: Strong Growth Ahead Driven by Research and Innovative Therapies
May 13, 2025 • EIN Presswire
Shionogi inks new hearing loss research deal with Cilcare
May 12, 2025 • The Pharma Letter
Shionogi & Co. GAAP EPS of ¥200.29, revenue of ¥438.27B
May 12, 2025 • Seeking Alpha
Shionogi aims to buy tobacco giant's pharma unit for $1bn
May 8, 2025 • pharmaphorum
Shionogi to acquire Japan Tobacco pharma companies for $1.1B
May 8, 2025 • BioWorld MedTech
Shionogi pushes 2030 vision forward with $1 billion acquisition
May 8, 2025 • The Pharma Letter
Bristol Myers' $40B US investment; Shionogi to buy Japanese drugmaker
May 8, 2025 • Endpoints News
Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal
May 7, 2025 • Nikkei Asia
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion
May 7, 2025 • Reuters
Shionogi To Buy Torii Pharmaceutical For About 150 Billion Yen, Nikkei Says
May 7, 2025 • MarketScreener
Global Virology Market Poised for Expansion, Projected to...
May 7, 2025 • PharmiWeb
Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma
May 7, 2025 • Bloomberg
Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion
May 7, 2025 • MarketScreener
Shionogi to buy Japan Tobacco’s Torii Pharma in a deal worth over $1B
May 7, 2025 • Seeking Alpha
Japan’s Nikkei Snaps 7-Day Winning Streak as US Tariff Worries Weigh
May 6, 2025 • Yomiuri Shimbun
Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments
May 5, 2025 • BioSpectrum Asia
Shionogi Raises Year-End Dividend Forecast to 33 Yen
Apr 25, 2025 • marketscreener.com
New England Journal of Medicine publishes phase III data showing single-dose Xofluza significantly reduces influenza virus transmission
Apr 25, 2025 • F. Hoffmann-La Roche Ltd
New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission
Apr 25, 2025 • BioSpace
Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants
Apr 3, 2025 • BioWorld Financial Watch
Comprehensive Insights Of The Global Invasive Aspergillosis Therapeutics Market: Key Drivers, Trends, And Forecast 2034
Mar 27, 2025 • EIN Presswire
Pneumonia Therapeutics Global Market Report 2025: An Analysis of Market Growth, Trends and Key Players
Mar 27, 2025 • EIN Presswire
Shionogi & Co Ltd: Shionogi Submits Supplemental New Drug Application For Ensitrelvir In Japan For Post-Exposure Prophylaxis Of Covid-19
Mar 27, 2025 • MarketScreener
ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
Mar 26, 2025 • Canada NewsWire
Apnimed to Participate in the 24th Annual Needham Virtual Healthcare Conference
Mar 26, 2025 • PR Newswire
Complicated Urinary Tract Infection Treatment Global Market Report 2025: Opportunities, Trends, And Forecasts To 2034
Mar 25, 2025 • EIN Presswire
In-Depth Analysis Of The Global Acquired Immunodeficiency Syndrome (AIDS) Market: Key Drivers, Trends, Growth
Mar 24, 2025 • EIN Presswire
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
Mar 19, 2025 • Benzinga
In the clinic for March 18, 2025
Mar 18, 2025 • BioWorld Financial Watch
In the clinic for March 14, 2025
Mar 14, 2025 • BioWorld Financial Watch
Quebec becomes first province to publicly reimburse APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP)
Mar 5, 2025 • Canada NewsWire
Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients
Feb 24, 2025 • 2 Minute Medicine
Approval for Fetroja in South Korea
Feb 24, 2025 • Pharma Letter
Shionogi gets approval in Japan for ADHD digital therapeutic
Feb 18, 2025 • pharmaphorum
Fragile X syndrome market to quadruple to $111.9 million in USA and Germany by 2030
Feb 18, 2025 • Pharma Letter
Chronic Refractory Cough Market Size to Reach USD 14.9 Billion by 2035, Impelled by Increasing Research & Development Activities
Feb 14, 2025 • BioSpace
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
Feb 4, 2025 • BioSpace
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
Jan 31, 2025 • PharmiWeb.com
The Global Premenstrual Syndrome (PMS) Treatment Market: A Path to Growth and Innovation
Jan 30, 2025 • EIN Presswire
Shionogi awarded $375m from HHS for preventative Covid-19 injectable
Jan 17, 2025 • Pharmaceutical Technology
Shionogi Receives Award Through BARDA’s Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations
Jan 16, 2025 • BioSpace
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations
Jan 16, 2025 • Business Wire
Sepsis Market to Surge Rapidly During 2024–2034, Highlights DelveInsight
Jan 9, 2025 • EIN Presswire

Links

www.shionogi.comLinkedInX (Twitter)Crunchbase